Patents by Inventor Jingrong Cao

Jingrong Cao has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Inhibitors of phosphatidylinositol 3-kinase
    Patent number: 8344153
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: June 9, 2010
    Date of Patent: January 1, 2013
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Kevin Michael Cottrell, Alex Aronov, Robert J. Davies, Jon H. Come, David Messersmith, Jinwang Xu, Upul Keerthi Bandarage, Jingrong Cao
  • DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES
    Publication number: 20120316186
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: February 23, 2012
    Publication date: December 13, 2012
    Inventors: Mark Ledeboer, David Messersmith, Francois Maltais, Huai Gao, Tiansheng Wang, Jingrong Cao, John Duffy, Gabriel Martinez-Botella, Cornelia Forster, Marion Wannamaker, Francesco Salituro, Albert Pierce, Luc Farmer, Valerie Marone
  • C-met protein kinase inhibitors
    Patent number: 8278306
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Grant
    Filed: October 5, 2011
    Date of Patent: October 2, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Upul Keerthi Bandarage, Jon H. Come, Craig Marhefka
  • ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
    Publication number: 20120202784
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: January 13, 2012
    Publication date: August 9, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, JR., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
  • AZAINDAZOLES USEFUL AS INHIBITORS OF KINASES
    Publication number: 20120165367
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Application
    Filed: July 29, 2011
    Publication date: June 28, 2012
    Inventors: Guy Brenchley, Jean-Damien Charrier, Steven Durrant, Ronald Knegtel, Sharn Ramaya, Shazia Keily, Jingrong Cao
  • CGRP receptor antagonists
    Patent number: 8163737
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Grant
    Filed: December 13, 2007
    Date of Patent: April 24, 2012
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Anderson, Andreas Termin, Sara Hadida-Ruah, Pramod Joshi, Sanghee Yoo, Daniele Bergeron, Hayley Binch, Jon Come, Jingrong Cao, Suganthi Nanthakumar, Elaine Krueger, John Maxwell, Arnaud Le Tiran, Yusheng Liao
  • C-MET PROTEIN KINASE INHIBITORS
    Publication number: 20120065213
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Application
    Filed: October 5, 2011
    Publication date: March 15, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • ISOINDOLINONE INHIBITORS OF PHOSPHATIDYLINOSITOL 3-KINASE
    Publication number: 20120040950
    Abstract: The present invention relates to compounds useful as inhibitors of PI3K, particularly of PI3K?. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: December 21, 2010
    Publication date: February 16, 2012
    Applicant: VERTEX PHARMACEUTICALS INCORPORATED
    Inventors: Alex Aronov, Jon H. Come, Robert J. Davies, Albert Charles Pierce, Philip N. Collier, Ronald Lee Grey, JR., Hardwin O'Dowd, James A. Henderson, Elaine B. Krueger, Arnaud Le Tiran, Yusheng Liao, David Messersmith, Jian Wang, Suganthini S. Nanthakumar, Jingrong Cao, Upul Keerthi Bandarage, Anne-Laure Grillot
  • Selective inhibitors of rock protein kinase and uses thereof
    Patent number: 8058271
    Abstract: Described herein are compounds that are useful as ROCK inhibitors. These compounds, and pharmaceutically acceptable compositions thereof, are useful for treating or lessening the severity of a variety of disorders, including cardiovascular, inflammatory, neurological, or proliferative diseases or disorders.
    Type: Grant
    Filed: May 10, 2007
    Date of Patent: November 15, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Jingrong Cao, Upul Bandarage, Jon Come, Craig Marhefka
  • Azaindazoles useful as inhibitors of kinases
    Patent number: 8017781
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinase. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders. The invention also provides processes for preparing compounds of the inventions.
    Type: Grant
    Filed: November 15, 2006
    Date of Patent: September 13, 2011
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Guy Brenchley, Jean-Damien Charrier, Steven Durrant, Ronald Knegtel, Sharn Ramaya, Shazia Sadiq, Jingrong Cao
  • CGRP receptor antagonists
    Patent number: 7842686
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Grant
    Filed: January 21, 2009
    Date of Patent: November 30, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Don Anderson, Andreas P. Termin, Pramod Joshi, Sara S. Hadida Ruah, Daniele Bergeron, Sanghee Yoo, Jingrong Cao
  • CGRP receptor antagonists
    Patent number: 7834000
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Grant
    Filed: June 13, 2007
    Date of Patent: November 16, 2010
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Corey Gutierrez, Andreas Termin, Sara Hadida-Ruah, Pramod Joshi, Daniele Bergeron, Sanghee Yoo, Hayley Binch, Jon Come, Jingrong Cao, Suganthi Nanthakumar
  • Inhibitors of c-JUN N-terminal kinases (JNK)
    Patent number: 7612065
    Abstract: The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Grant
    Filed: March 28, 2007
    Date of Patent: November 3, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Susanne Wilke, Francesco Salituro, Edmund Harrington, Jingrong Cao, Guy Bemis, Huai Gao
  • DEAZAPURINES USEFUL AS INHIBITORS OF JANUS KINASES
    Publication number: 20090227607
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: October 3, 2008
    Publication date: September 10, 2009
    Inventors: Mark Ledeboer, David Messersmith, Francois Maltais, Huai Gao, Tiansheng Wang, Jingrong Cao, John Duffy, Gabriel Martinez-Botella, Cornelia Forster, Marion Wannamaker, Francesco Salituro, Albert Pierce, Luc Farmer, Valerie Marone
  • CGRP RECEPTOR ANTAGONISTS
    Publication number: 20090176769
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Application
    Filed: December 13, 2007
    Publication date: July 9, 2009
    Inventors: Corey Anderson, Andreas Termin, Sara Hadida-Ruah, Pramod Joshi, Sanghee Yoo, Daniele Bergeron, Hayley Binch, Jon Come, Jingrong Cao, Suganthi Nanthakumar, Elaine Krueger, John Maxwell, Arnaud Le Tiran, Yusheng Liao
  • Azaindoles useful as inhibitors of rock and other protein kinases
    Patent number: 7514448
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Grant
    Filed: April 4, 2005
    Date of Patent: April 7, 2009
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Jeremy Green, Andrew Miller, Juan-Miguel Jimenez, Craig Marhefka, Jingrong Cao, John Court, Upul Bandarage, Huai Gao, Suganthini Nanthakumar
  • Deazapurines useful as inhibitors of Janus kinases
    Publication number: 20090088445
    Abstract: The present invention relates to compounds useful as inhibitors of protein kinases, particularly of JAK family kinases. The invention also provides pharmaceutically acceptable compositions comprising said compounds and methods of using the compositions in the treatment of various disease, conditions, or disorders.
    Type: Application
    Filed: April 5, 2007
    Publication date: April 2, 2009
    Inventors: Mark Ledeboer, David Messersmith, Francois Maltais, Huai Gao, Tiansheng Wang, Jingrong Cao, John Duffy, Gabriel Martinez-Botella, Cornelia Forster, Marion Wannamaker, Francesco Salituro, Albert Pierce, Luc Farmer, Valerie Marone
  • Isoxazole compositions useful as inhibitors of ERK
    Patent number: 7354919
    Abstract: Described herein are compounds that are useful as protein kinase inhibitors, especially inhibitors of ERK, having the formula: where A, B, R1, R2, T and Ht are described in the specification. The compounds are useful for treating diseases in mammals that are alleviated by a protein, kinase inhibitor, particularly diseases such as cancer, inflammatory disorders, restenosis, and cardiovascular disease.
    Type: Grant
    Filed: July 24, 2003
    Date of Patent: April 8, 2008
    Assignee: Vertex Pharmaceuticals Incorporated
    Inventors: Michael R. Hale, James W. Janetka, Francois Maltais, Jingrong Cao
  • Inhibitors of c-Jun N-terminal kinases (JNK)
    Publication number: 20080033022
    Abstract: The present invention relates to inhibitors of JNK, a mammalian protein kinase involved cell proliferation, cell death and response to extracellular stimuli. The invention also relates to methods for producing these inhibitors. The invention also provides pharmaceutical compositions comprising the inhibitors of the invention and methods of utilizing those compositions in the treatment and prevention of various disorders.
    Type: Application
    Filed: March 28, 2007
    Publication date: February 7, 2008
    Inventors: Francesco Salituro, Guy Bemis, Susanne Wilke, Jeremy Green, Jingrong Cao, Huai Gao, Edmund Harrington
  • CGRP receptor antagonists
    Publication number: 20080004261
    Abstract: The present invention relates to CGRP receptor antagonists, pharmaceutical compositions thereof, and methods therewith for treating CGRP receptor-mediated diseases and conditions.
    Type: Application
    Filed: June 13, 2007
    Publication date: January 3, 2008
    Inventors: Corey Gutierrez, Andreas Termin, Sara Hadida-Ruah, Pramod Joshi, Daniele Bergeron, Sanghee Yoo, Hayley Binch, Jon Come, Jingrong Cao, Suganthi Nanthakumar